Compare USCB & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | ABEO |
|---|---|---|
| Founded | 2002 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 307.5M |
| IPO Year | 2021 | 2005 |
| Metric | USCB | ABEO |
|---|---|---|
| Price | $19.80 | $5.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $23.00 | $20.00 |
| AVG Volume (30 Days) | 39.7K | ★ 918.3K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | 7.26 | ★ 165.16 |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $26.46 | $1,024.31 |
| Revenue Next Year | $9.67 | $145.42 |
| P/E Ratio | $38.24 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $15.57 | $4.00 |
| 52 Week High | $20.79 | $7.54 |
| Indicator | USCB | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 51.58 |
| Support Level | $17.83 | $5.24 |
| Resistance Level | $20.17 | $5.64 |
| Average True Range (ATR) | 0.44 | 0.23 |
| MACD | 0.15 | -0.02 |
| Stochastic Oscillator | 81.09 | 47.52 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.